First Report

U.S. Patient and Clinician Experiences With the inFlow™ Urinary Prosthesis for Permanent Urinary Retention in Women

Leanne Schimke, MSN, FNP-C, CRNP, CUNP; Kevin M. Connolly

Disclosures

Urol Nurs. 2020;40(2):61-73. 

In This Article

Abstract and Introduction

Abstract

The inFlow™ intraurethral Valve Pump and Activator (collectively, the inFlow urinary prosthesis) received approval from the u.s. Food and Drug Administration center for Devices and radiological Health in 2014 for the treatment of permanent urinary retention. This article provides an overview of the device and presents findings of a post-market survey that examined both patient and caregiver experiences with inFlow among a sample of u.s. women. A first-person account of a clinician's experience with the device provides a unique perspective and enhanced understanding of this treatment option.

Introduction

Treatment of permanent urinary retention (PUR), defined by Medicare as retention that is not expected to be corrected medically or surgically within the next three months, is a vexing problem for both clinicians and women. In 2014, the Food and Drug Association (FDA) Center for Devices and Radiological Health approved an innovative alternative treatment device for women with PUR named inFlow™ Urinary Prosthesis. The device is not available for men. This article provides an overview of inFlow and presents findings of a study that examined both patient and caregiver experiences with inFlow among a sample of women in the United States. Experiences are based on a company-sponsored, post-market survey of long-term users. To complement patient and caregiver reports, a first-person account of a clinician's experience with inFlow provides the urology provider with a unique perspective and enhanced understanding of this alternative treatment option.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....